FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037199705> ?p ?o ?g. }

• W3037199705 endingPage "21" @default.
• W3037199705 startingPage "15" @default.
• W3037199705 abstract "to evaluate the efficiency and safety of phenazopyridine for the treatment of patients with uncomplicated lower urinary tract infection, accompanied by pain.A multicenter double-blind, randomized, placebo-controlled study with parallel groups to evaluate the efficacy and safety of phenazopyridine in patients with acute uncomplicated cystitis was performed. A total of 60 women were divided into two groups of 30 patients. In the main group (average age 32.6+/-7.4 years) phenazopyridine was prescribed (2 tablets of 100 mg p.o., with a total dose of 200 mg, once). In the control group, patients (mean age 35.53+/-8.79 years) received a placebo according to the same scheme. To evaluate the efficiency of treatment, the severity of the main symptoms 6 hours after taking the drug was analyzed. After that, patients started antibiotic therapy. They were followed-up for the next three days. The tolerance of therapy was evaluated by the presence of adverse events.All 30 patients taking phenazopyridine had an improvement after 6 hours, and the most frequent response was significant improvement (43.3%). The responses of patients in the main group significantly (p<0.05) differed from responses of patients in the control group. Six hours after taking phenazopyridine/placebo, the severity of all values according to VAS score, including the degree of general discomfort, pain during urination and increased frequency of urination improved significantly in the main group compared to the control group. The average assessment of general discomfort in the main group decreased by 53.4% in comparison with 28.8% in the control group, while the severity of pain during urination and urination frequency decreased by 57.4 vs. 35.9% and 39.6 vs. 27.6%, respectively. An analysis of the time before the complete absence of the general discomfort was performed. In the main group this period of time was significantly less than in the control group (p<0.05). There were no serious adverse events while taking phenazopyridine. Rate of adverse events was comparable between two groups.The results of the study showed that phenazopyridine is an effective and well-tolerated drug for symptomatic therapy in patients with acute uncomplicated cystitis and can be recommended in addition to etiological therapy." @default.
• W3037199705 created "2020-07-02" @default.
• W3037199705 creator A5002104650 @default.
• W3037199705 creator A5010457132 @default.
• W3037199705 creator A5021209929 @default.
• W3037199705 creator A5058317314 @default.
• W3037199705 creator A5060749289 @default.
• W3037199705 creator A5088006525 @default.
• W3037199705 date "2020-06-29" @default.
• W3037199705 modified "2023-10-01" @default.
• W3037199705 title "Efficiency and safety of phenazopyridine for treatment of uncomplicated urinary tract infection: results of multi-center, randomized, placebo-controlled, clinical study" @default.
• W3037199705 doi "https://doi.org/10.18565/urology.2020.3.15-21" @default.
• W3037199705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32597580" @default.
• W3037199705 hasPublicationYear "2020" @default.
• W3037199705 type Work @default.
• W3037199705 sameAs 3037199705 @default.
• W3037199705 citedByCount "1" @default.
• W3037199705 countsByYear W30371997052023 @default.
• W3037199705 crossrefType "journal-article" @default.
• W3037199705 hasAuthorship W3037199705A5002104650 @default.
• W3037199705 hasAuthorship W3037199705A5010457132 @default.
• W3037199705 hasAuthorship W3037199705A5021209929 @default.
• W3037199705 hasAuthorship W3037199705A5058317314 @default.
• W3037199705 hasAuthorship W3037199705A5060749289 @default.
• W3037199705 hasAuthorship W3037199705A5088006525 @default.
• W3037199705 hasConcept C126322002 @default.
• W3037199705 hasConcept C142724271 @default.
• W3037199705 hasConcept C168563851 @default.
• W3037199705 hasConcept C175768497 @default.
• W3037199705 hasConcept C197934379 @default.
• W3037199705 hasConcept C204787440 @default.
• W3037199705 hasConcept C27081682 @default.
• W3037199705 hasConcept C42219234 @default.
• W3037199705 hasConcept C535046627 @default.
• W3037199705 hasConcept C71924100 @default.
• W3037199705 hasConcept C77411442 @default.
• W3037199705 hasConceptScore W3037199705C126322002 @default.
• W3037199705 hasConceptScore W3037199705C142724271 @default.
• W3037199705 hasConceptScore W3037199705C168563851 @default.
• W3037199705 hasConceptScore W3037199705C175768497 @default.
• W3037199705 hasConceptScore W3037199705C197934379 @default.
• W3037199705 hasConceptScore W3037199705C204787440 @default.
• W3037199705 hasConceptScore W3037199705C27081682 @default.
• W3037199705 hasConceptScore W3037199705C42219234 @default.
• W3037199705 hasConceptScore W3037199705C535046627 @default.
• W3037199705 hasConceptScore W3037199705C71924100 @default.
• W3037199705 hasConceptScore W3037199705C77411442 @default.
• W3037199705 hasLocation W30371997051 @default.
• W3037199705 hasLocation W30371997052 @default.
• W3037199705 hasOpenAccess W3037199705 @default.
• W3037199705 hasPrimaryLocation W30371997051 @default.
• W3037199705 hasRelatedWork W1977915442 @default.
• W3037199705 hasRelatedWork W2064879719 @default.
• W3037199705 hasRelatedWork W2085830368 @default.
• W3037199705 hasRelatedWork W2088746205 @default.
• W3037199705 hasRelatedWork W3159250744 @default.
• W3037199705 hasRelatedWork W4233016836 @default.
• W3037199705 hasRelatedWork W4235671009 @default.
• W3037199705 hasRelatedWork W4256514411 @default.
• W3037199705 hasRelatedWork W4288392727 @default.
• W3037199705 hasRelatedWork W4292236216 @default.
• W3037199705 hasVolume "3_2020" @default.
• W3037199705 isParatext "false" @default.
• W3037199705 isRetracted "false" @default.
• W3037199705 magId "3037199705" @default.
• W3037199705 workType "article" @default.